0000950170-24-138629.txt : 20241219
0000950170-24-138629.hdr.sgml : 20241219
20241219185742
ACCESSION NUMBER: 0000950170-24-138629
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20241218
FILED AS OF DATE: 20241219
DATE AS OF CHANGE: 20241219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AULIN SHERRY
CENTRAL INDEX KEY: 0001862144
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36687
FILM NUMBER: 241564680
MAIL ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A0
ZIP: V5G 48W
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001582313
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 980661854
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
BUSINESS PHONE: (604) 484-3300
MAIL ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
4
1
ownership.xml
4
X0508
4
2024-12-18
false
0001582313
Xenon Pharmaceuticals Inc.
XENE
0001862144
AULIN SHERRY
200 - 3650 GILMORE WAY
BURNABY
A1
V5G 4W8
BRITISH COLUMBIA, CANADA
false
true
false
false
Chief Financial Officer
false
Common Shares
2024-12-18
4
M
false
9334
9.44
A
9334
D
Common Shares
2024-12-18
4
F
false
2135
41.28
D
7199
D
Common Shares
2024-12-18
4
S
false
7199
41.23
D
0
D
Common Shares
2024-12-18
4
M
false
16000
11.58
A
16000
D
Common Shares
2024-12-18
4
F
false
4490
41.28
D
11510
D
Common Shares
2024-12-18
4
S
false
11510
41.19
D
0
D
Stock Option (Right to Buy)
9.44
2024-12-18
4
M
false
9334
0
D
2029-09-15
Common Shares
9334
0
D
Stock Option (Right to Buy)
11.58
2024-12-18
4
M
false
16000
0
D
2030-03-11
Common Shares
16000
6000
D
Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The shares subject to the option are fully vested and exercisable.
/s/ Nathaniel Adams, Attorney-in-fact
2024-12-18